Octyltriethoxysilane (OTES) is an organosilicon compound that serves as a precursor for the production of silica-based materials. It is typically synthesized through the reaction of octyl chloride with triethoxysilane. OTES is widely studied for its potential applications in various fields, including coatings, adhesives, sealants, and nanocomposites. The hydrophobic nature of the octyl group makes it a valuable component in the development of water-repellent surfaces. OTES has been investigated for its ability to improve the adhesion and durability of coatings, as well as to enhance the mechanical properties of polymers. Researchers are particularly interested in its use as a modifier for silica nanoparticles, which can lead to the creation of materials with improved performance characteristics.'
| ID Source | ID |
|---|---|
| PubMed CID | 76262 |
| CHEMBL ID | 3185786 |
| CHEBI ID | 136012 |
| SCHEMBL ID | 26406 |
| MeSH ID | M0503781 |
| Synonym |
|---|
| prosil 9234 |
| einecs 220-941-2 |
| triethoxyoctylsilane |
| y 9187 |
| a 137 (coupling agent) |
| nsc 42964 |
| prosil 9202 |
| dynasylan octeo |
| silquest a 137 |
| 2943-75-1 |
| octyltriethoxysilane , |
| nsc-42964 |
| nsc42964 |
| octyl(triethoxy)silane |
| n-octyltriethoxysilane |
| silane, triethoxyoctyl- |
| oleth-30 |
| triethoxy(octyl)silane, deposition grade, 98%, 99.99% trace metals basis |
| triethoxy(octyl)silane, >=97.5% |
| NCGC00164371-01 |
| triethoxy(octyl)silane |
| CHEBI:136012 |
| O0171 |
| triethoxy-n-octylsilane |
| NCGC00164371-02 |
| dtxsid2029246 , |
| NCGC00257255-01 |
| dtxcid909246 |
| tox21_303648 |
| cas-2943-75-1 |
| unii-ldc331p08e |
| ec 220-941-2 |
| triethoxycaprylylsilane |
| ldc331p08e , |
| FT-0634574 |
| triethoxycaprylsilane |
| caprylyltriethoxysilane |
| triethoxycaprylylsilane [inci] |
| S12775 |
| AKOS015901613 |
| SCHEMBL26406 |
| co9835 |
| triethoxy-n-octyltriethoxysilane |
| union carbide a-137 |
| CHEMBL3185786 |
| mfcd00039883 |
| BCP15824 |
| DB11267 |
| BS-16883 |
| Q27282931 |
| octyl-triethoxy-silane |
| triethoxy-n-ctylsilane |
| n-ctyltriethoxysilane |
| triethoxy(ctyl)silane |
| triethoxy ctyl silane |
| ctyltriethoxysilane |
| 156327-81-0 |
| CS-0006246 |
| HY-91054 |
| Class | Description |
|---|---|
| organosilicon compound | An organosilicon compound is a compound containing at least one carbon-silicon bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 54.4827 | 0.0002 | 21.2231 | 8,912.5098 | AID743040 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 47.9687 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743079 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 38.9000 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 61.1306 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||